Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.57 |
| ▸ | ITGAV | P06756 | 7/20 | 0.57 |
| ▸ | EEF2K | O00418 | 3/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194759 | 0.94 | ITGB3 (0.52) | ITGB3ITGAVEEF2KITGA2BHDAC8 | |
| SCHEMBL7774747 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVEEF2KITGA2BHDAC8 | |
| SCHEMBL6367673 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVITGA2BL3MBTL1MEN1 | |
| SCHEMBL6366667 | 0.89 | ITGB3 (0.60) | ITGB3ITGAVEEF2KALDH1A1ATM | |
| SCHEMBL6368255 | 0.89 | ITGB3 (0.58) | ITGB3ITGAVEEF2KITGA2BHDAC8 | |
| SCHEMBL2833035 | 0.84 | ITGB3 (0.48) | ITGB3ITGA2BHDAC8HDAC6MEN1 | |
| SCHEMBL6368621 | 0.83 | ITGB3 (0.46) | ITGB3ITGAVITGA2BHDAC8HDAC6 | |
| SCHEMBL6367010 | 0.83 | ITGB3 (0.46) | ITGB3ITGAVITGA2BHDAC8HDAC6 | |
| SCHEMBL7198477 | 0.83 | MAPT (0.45) | ITGB3ITGAVHDAC8HDAC6ALDH1A1 | |
| SCHEMBL7194908 | 0.81 | ITGB3 (0.51) | ITGB3ITGAVITGA2BHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677308-B1 | INTEGRIN ANTAGONISTS; ANTITUMOR, ANTIMETASTASIS, ANTICARCINOGENIC AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS; OSTEOPOROSIS | G. D. SEARLE & CO. | 2004-01-13 | — | — | US | claimed |
| EP-0889876-B1 | META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES | SEARLE & CO (US) | 2001-07-25 | — | — | EP | claimed |
| EP-0889876-A1 | META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES | G.D. SEARLE & CO. (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1997036861-A1 | META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | claimed |
| US-7385080-B2 | Method for producing optically active β-phenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2008-06-10 | — | — | US | disclosed |
| US-20050176821-A1 | Meta-substituted phenylene sulphonamide derivatives | G. D. SEARLE & CO. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6677308-B1 | INTEGRIN ANTAGONISTS; ANTITUMOR, ANTIMETASTASIS, ANTICARCINOGENIC AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS; OSTEOPOROSIS | G. D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| EP-0889876-B1 | META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES | SEARLE & CO (US) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176821-A1 | Meta-substituted phenylene sulphonamide derivatives | ITGB3, ITGB1, ITGA5 | ITGB3 1/4885ITGAV 6/4885EEF2K 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.